Molecular profiling of breast cancer: clinical implications.
Molecular profiling of breast cancer: clinical implications.
复制标题
乳腺癌的分子分析：临床意义。
DOI：
10.1038/sj.bjc.6601667
复制
发表时间：
2004-03-22
影响因子：
8.8
通讯作者：
Ashworth, A
中科院分区：
文献类型：
--
作者：
Cleator, S;Ashworth, A
乳腺癌通常根据临床分期、细胞形态和少量标记物的免疫组织化学分析进行亚分类。基因表达微阵列和相关技术的最新发展为进行更详细的疾病分析提供了机会。可以预见，从这些研究中产生的分子分类将比其病理前身在限制治疗那些最有可能受益的患者方面更有力。这可能会导致辅助化疗的使用频率大大降低。此外，在接受资助的人中，受益的比例更高。如果采用，这将在减少不必要的毒性方面为患者提供可观的好处，并具有重大的卫生经济影响。
Breast cancers are routinely subcategorised on the basis of clinical stage, cellular morphology and immunohistochemical analysis of a small number of markers. The recent development of gene expression microarray and related technologies provides an opportunity to perform more detailed profiling of the disease. It is anticipated that the molecular classification arising from such studies will be more powerful than its pathological predecessor at confining treatment to those patients who are most likely to benefit. It is likely that this will result in a much less frequent use of adjuvant chemotherapy. Furthermore, of those who do receive it, a higher proportion will benefit. If adopted, this will offer considerable patient benefits in terms of reducing unnecessary toxicity and have major health economic implications.